STRAMSEN BIOTECH, INC
Dennis Antippas - MBA
Chief Operating Officer (COO)
Mr. Dennis Antippas has been appointed as the Chief Operating Officer (COO) of Stramsen Biotech Inc. This strategic addition to the executive team brings a wealth of experience and academic credentials to the organization.
Mr. Antippas holds a Master of Business Administration (MBA) with a specialization in Finance and Management from Fordham University, a prestigious institution known for its rigorous business programs. His educational background is further strengthened by a Bachelor of Science in Industrial Management from Carnegie Mellon University, an institution renowned for its cutting-edge approach to technology and management education.
Dennis possesses extensive experience in managing large departments within the pharmaceutical industry, having spent nine years with the Swiss-American pharmaceutical corporation Novartis International AG. Throughout his tenure, he held various senior management roles in the United States and several European countries. His key positions at Novartis included Associate Director of Global Finance, Business Planning Manager for Global Finance, Plant Controller in Nyon, Switzerland, and Head of Country Finance for the Czech Republic and Slovakia.
As Plant Controller in Nyon, Switzerland, Dennis provided comprehensive financial leadership and spearheaded multiple process-enhancing initiatives to augment the Finance department's capabilities in support of a $140 million manufacturing facility. Subsequently, as Associate Director of Global Finance, he consolidated financial results for 65 countries, presenting analyses of results and trends to senior leadership and formulating strategic business recommendations to inform decision-making processes.
In his role as Head of Country Finance for the Czech Republic and Slovakia, Dennis led the finance department of a $50 million region comprising two separate legal entities. Prior to this, as Business Planning Manager for Global Finance , he implemented process improvement initiatives for business unit reporting by standardizing global and regional planning communications and submissions.
Dennis's trajectory at Novartis International AG demonstrates a consistent pattern of increasing responsibility and a proven ability to manage complex financial operations across diverse geographical and functional contexts. His experience in consolidating financial data, driving process improvements, and providing strategic insights positions him as a valuable asset in the pharmaceutical industry's financial management sphere.
This combination of advanced business acumen and industrial management expertise positions Mr. Antippas as a valuable asset to Stramsen Biotech Inc. His academic foundation, coupled with his professional experience, is expected to contribute significantly to the company's operational efficiency and strategic growth in the competitive biopharmaceutical sector.
‘At ConvaTec, Dennis excelled as Finance Director for Advanced Wound Care, where he led North America FP&A for a $160M revenue business. His development of cutting-edge financial models for sales forecasting and performance reporting proved invaluable. Dennis's strategic insights provided crucial financial guidance on M&A opportunities, while his participation in a strategic task force to outsource reporting drove significant process improvements.
Dennis brings a wealth of diverse industry experience that extends far beyond pharmaceuticals, positioning him as an invaluable asset to Stramsen Biotech Inc.:
As Vice President of Finance at 8Greens, a New York City-based company, Dennis demonstrated exceptional leadership and strategic acumen. He spearheaded FP&A and accounting for this private equity-backed omni-channel consumer products company, driving sales growth over 30% through strategic channel expansion and innovative product lines. His implementation of sophisticated profitability models led to an impressive 100% growth in mass/grocery channels and a 25% annual growth on Amazon. Dennis's financial expertise was instrumental in managing investor reports and due diligence, culminating in a successful company sale. Moreover, his cost-optimization strategies resulted in a remarkable 25% reduction in cost of goods through efficiency improvements.
Dennis's tenure at L'Oreal USA as AVP Finance for L'Oreal Professional, Kerastase, and Shu Uemura brands showcased his ability to drive substantial growth. Overseeing a P&L for 3 brands totaling over $150M in revenues, he transformed sales, marketing, and pricing strategies, resulting in a $10M (20%) increase in revenue. His leadership in the budgeting process and development of customer P&Ls drove profitable channel growth, while his e-commerce initiatives led to an astounding 130% growth in online sales.
As AVP Finance at SalonCentric, Dennis managed FP&A for a $1B division, including $250M in SG&A expenses. His meticulous oversight ensured compliance with sales contracts and rigorous performance monitoring, demonstrating his ability to handle large-scale financial operations with precision and effectiveness.
Dennis's track record of driving growth, optimizing financial performance, and providing strategic leadership across diverse industries makes him an exceptional addition to Stramsen Biotech Inc.'s executive team. His expertise will be instrumental in guiding our company's financial strategy as we revolutionize the biopharmaceutical industry with our innovative plant-based approach to medicine.